| Downregulation of circ-YES1 suppresses NSCLC migration and proliferation through the miR-142-3p-HMGB1 axis. | Downregulation of circ-YES1 suppresses NSCLC migration and proliferation through the miR-142-3p-HMGB1 axis.
Jin M, Wang Y, Zhou D, Liu W, Han R, Chi Y., Free PMC Article | 08/10/2023 |
| YES1 Kinase Mediates the Membrane Removal of Rescued F508del-CFTR in Airway Cells by Promoting MAPK Pathway Activation via SHC1. | YES1 Kinase Mediates the Membrane Removal of Rescued F508del-CFTR in Airway Cells by Promoting MAPK Pathway Activation via SHC1.
Barros P, Matos AM, Matos P, Jordan P., Free PMC Article | 07/5/2023 |
| YES1 Is a Druggable Oncogenic Target in SCLC. | YES1 Is a Druggable Oncogenic Target in SCLC.
Redin E, Garrido-Martin EM, Valencia K, Redrado M, Solorzano JL, Carias R, Echepare M, Exposito F, Serrano D, Ferrer I, Nunez-Buiza A, Garmendia I, García-Pedrero JM, Gurpide A, Paz-Ares L, Politi K, Montuenga LM, Calvo A. | 11/26/2022 |
| Matrix Mechanotransduction via Yes-Associated Protein in Human Lamina Cribrosa Cells in Glaucoma. | Matrix Mechanotransduction via Yes-Associated Protein in Human Lamina Cribrosa Cells in Glaucoma.
Murphy R, Irnaten M, Hopkins A, O'Callaghan J, Stamer WD, Clark AF, Wallace D, O'Brien CJ., Free PMC Article | 02/19/2022 |
| EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis. | EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis.
Mao L, Yuan W, Cai K, Lai C, Huang C, Xu Y, Zhong S, Yang C, Wang R, Zeng P, Huang H, Chen Z, Chen Z., Free PMC Article | 01/15/2022 |
| Scribble sub-cellular localization modulates recruitment of YES1 to regulate YAP1 phosphorylation. | Scribble sub-cellular localization modulates recruitment of YES1 to regulate YAP1 phosphorylation.
Zhao D, Yin Z, Soellner MB, Martin BR. | 01/8/2022 |
| Overexpression of YES1 is associated with favorable prognosis and increased platinum-sensitivity in patients with epithelial ovarian cancer. | Overexpression of YES1 is associated with favorable prognosis and increased platinum-sensitivity in patients with epithelial ovarian cancer.
Zhou Y, Chen P, Huang Q, Wan T, Jiang Y, Jiang S, Yan S, Zheng M. | 04/17/2021 |
| MiR-133 Targets YES1 and Inhibits the Growth of Triple-Negative Breast Cancer Cells. | MiR-133 Targets YES1 and Inhibits the Growth of Triple-Negative Breast Cancer Cells.
Zhang G, Wang J, Zheng R, Song B, Huang L, Liu Y, Hao Y, Bai X., Free PMC Article | 01/9/2021 |
| Genome-Wide Analysis Identifies Two Susceptibility Loci for Positive Thyroid Peroxidase and Thyroglobulin Antibodies. | Genome-Wide Analysis Identifies Two Susceptibility Loci for Positive Thyroid Peroxidase and Thyroglobulin Antibodies.
Matana A, Boutin T, Torlak V, Brdar D, Gunjača I, Kolčić I, Boraska Perica V, Punda A, Polašek O, Barbalić M, Hayward C, Zemunik T. | 11/21/2020 |
| YES1 is essential for NSCLC carcinogenesis. YES1 overexpression induced metastatic spread in preclinical in vivo models. YES1 genetic depletion by CRISPR/Cas9 technology significantly reduced tumor growth and metastasis. | YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
Garmendia I, Pajares MJ, Hermida-Prado F, Ajona D, Bértolo C, Sainz C, Lavín A, Remírez AB, Valencia K, Moreno H, Ferrer I, Behrens C, Cuadrado M, Paz-Ares L, Bustelo XR, Gil-Bazo I, Alameda D, Lecanda F, Calvo A, Felip E, Sánchez-Céspedes M, Wistuba II, Granda-Diaz R, Rodrigo JP, García-Pedrero JM, Pio R, Montuenga LM, Agorreta J. | 03/21/2020 |
| YES1 plays an important role in the emergence of resistance to HER2-targeted drugs. | YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers.
Takeda T, Yamamoto H, Suzawa K, Tomida S, Miyauchi S, Araki K, Nakata K, Miura A, Namba K, Shien K, Soh J, Shien T, Kitamura Y, Sendo T, Toyooka S., Free PMC Article | 03/21/2020 |
| The downregulation of miR-199a contributes to paclitaxel (PTX) resistance in prostate cancer. YES1 mediates the regulation of miR-199a in prostate cancer PTX resistance. | MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1.
Chen L, Cao H, Feng Y. | 10/6/2018 |
| findings identify acquired amplification of YES1 as a recurrent and targetable mechanism of resistance to EGFR inhibition in EGFR-mutant lung cancers and demonstrate the utility of transposon mutagenesis in discovering clinically relevant mechanisms of drug resistance. | YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.
Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, Germer S, Yu HA, Jordan EJ, Paik PK, Janjigian YY, Chaft JE, Wang L, Jungbluth AA, Middha S, Spraggon L, Qiao H, Lovly CM, Kris MG, Riely GJ, Politi K, Varmus H, Ladanyi M., Free PMC Article | 09/8/2018 |
| Study on the role of miR-140-5p in inhibiting tumorigenesis in gastric cancer thru targeting YES proto-oncogene 1(YES1). | miR-140-5p suppresses the proliferation, migration and invasion of gastric cancer by regulating YES1.
Fang Z, Yin S, Sun R, Zhang S, Fu M, Wu Y, Zhang T, Khaliq J, Li Y., Free PMC Article | 05/19/2018 |
| Our results suggest that H19 functions as a competitive endogenous RNA (ceRNA) by acting as a sink for miR-17-5p, revealing a potential ceRNA regulatory network involving H19 and miR-17-5p with a role in the modulation of YES1 expression | Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer.
Liu L, Yang J, Zhu X, Li D, Lv Z, Zhang X. | 06/24/2017 |
| c-Yes plays an important role in migration and invasion of epithelial ovarian cancer. | c-Yes enhances tumor migration and invasion via PI3K/AKT pathway in epithelial ovarian cancer.
Jin Y, Huang M, Wang Y, Yi C, Deng Y, Chen Y, Jiang L, Wang J, Shen Q, Liu R, QinghuaXi. | 06/3/2017 |
| Up-regulation of miR-210 inhibits hepatocellular carcinoma cell proliferation. Yes1 is a target of miR-210 and affects cell proliferation in HCC. | Up-regulation of microRNA-210 inhibits proliferation of hepatocellular carcinoma cells by targeting YES1.
Tan W, Lim SG, Tan TM., Free PMC Article | 11/12/2016 |
| findings indicate that miR-203 induces the apoptosis of KB cells by directly targeting Yes-1, suggesting its application in anti-cancer therapeutics | miR-203 downregulates Yes-1 and suppresses oncogenic activity in human oral cancer cells.
Lee SA, Kim JS, Park SY, Kim HJ, Yu SK, Kim CS, Chun HS, Kim J, Park JT, Go D, Kim DK. | 06/28/2016 |
| Results demonstrate a unique role for Yes in phosphorylation of FAK and in promoting PCa metastasis. Therefore, phosphorylated FAK Y861 and increased Yes expression may be predictive markers for PCa metastasis. | Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells.
Chatterji T, Varkaris AS, Parikh NU, Song JH, Cheng CJ, Schweppe RE, Alexander S, Davis JW, Troncoso P, Friedl P, Kuang J, Lin SH, Gallick GE., Free PMC Article | 03/19/2016 |
| Increased YES/SFK activation might serve as a clinical biomarker for predicting tumor resistance to IGF-1R inhibition. | IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
Wan X, Yeung C, Heske C, Mendoza A, Helman LJ., Free PMC Article | 01/23/2016 |
| YES1 and YAP transcript levels were higher in liver metastases of patients with colon cancer after 5FU-based neoadjuvant chemotherapy. | Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis.
Touil Y, Igoudjil W, Corvaisier M, Dessein AF, Vandomme J, Monté D, Stechly L, Skrypek N, Langlois C, Grard G, Millet G, Leteurtre E, Dumont P, Truant S, Pruvot FR, Hebbar M, Fan F, Ellis LM, Formstecher P, Van Seuningen I, Gespach C, Polakowska R, Huet G., Free PMC Article | 10/18/2014 |
| YES kinase as a proximal glucose-specific signal in the Cdc42-signaling cascade. | YES, a Src family kinase, is a proximal glucose-specific activator of cell division cycle control protein 42 (Cdc42) in pancreatic islet β cells.
Yoder SM, Dineen SL, Wang Z, Thurmond DC., Free PMC Article | 06/7/2014 |
| we identified CRKL/YES as critical interrelated pathways necessary for rhabdomyosarcoma cell growth and survival and suggest a potential therapeutic role of SRC family kinase inhibition in the treatment of rhabdomyosarcoma. | Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth.
Yeung CL, Ngo VN, Grohar PJ, Arnaldez FI, Asante A, Wan X, Khan J, Hewitt SM, Khanna C, Staudt LM, Helman LJ., Free PMC Article | 02/15/2014 |
| Expression of HPV type 16 E7 resulted in increase in Src and Yes proteins level, but did not alter the level of Fyn. | Activation of Src, Fyn and Yes non-receptor tyrosine kinases in keratinocytes expressing human papillomavirus (HPV) type 16 E7 oncoprotein.
Szalmás A, Gyöngyösi E, Ferenczi A, László B, Karosi T, Csomor P, Gergely L, Veress G, Kónya J., Free PMC Article | 09/14/2013 |
| Taken together, our findings demonstrate that Yes and Lyn phosphorylate EGFR at Y1101, which influences EGFR nuclear translocation in this model of cetuximab resistance. | Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor.
Iida M, Brand TM, Campbell DA, Li C, Wheeler DL., Free PMC Article | 04/13/2013 |